Drug Trial Radar · NCT02314819
A Phase III Trial Evaluating Fruquintinib Efficacy and Safety in 3+ Line Colorectal Cancer Patients (FRESCO)
Last checked: Nov 19, 2026Latest source record: Feb 17, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
416
Actual
Start
Dec 2014
Primary completion
Jan 2017
Study completion Jan 17, 2017
Sponsor
- Lead sponsor
- Hutchison Medipharma LimitedIndustry
- Sponsor type
- Industry
- Collaborators
- Fudan University; Eighty-One Hospital of People's Liberation Army
- First posted
- Dec 11, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Fruquintinib administered at 5mg once daily(QD) in 4 weeks treatment cycle (three weeks on and one week off) was well tolerated and demonstrated encouraging preliminary clinical antitumor activity in patients with metastatic colorectal cancer (CRC) in phase Ib and phase 2 study. This study is aimed to evaluate the efficacy and safety of Fruquintinib in the treatment of patients with metastatic CRC who have progressed after second line or above standard chemotherapy
Conditions
- Colorectal Cancer
Interventions
fruquintinibDrug
fruquintinib is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/ 1 week off
placeboDrug
fruquintinib placebo is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/ 1 week off
Primary outcomes
What the sponsor says the trial is designed to measure.
- overall survivalTime frame: from randomization until death due to any cause, assessed up to 2 year
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
Hutchison Medi Pharma Investigational Site
Hefei, Anhui, China
Hutchison Medi pharma Investigational Site
Beijing, Beijing Municipality, China
Hutchison Medi Pharma Investigational Site
Guangzhou, Guangdong, China
Hutchison Medi Pharma investigational site
Shenzhen, Guangdong, China
Hutchison Medi Pharma Investigational Site
Liuzhou, Guangxi, China
Hutchison Medi Pharma Investigational Site
Harbin, Heilongjiang, China
Hutchison Medi Pharma Investigational Site
Changsha, Hunan, China
Hutchison Medi Pharma Investigational Site
Changzhou, Jiangsu, China
Hutchison Medi Pharma Investigational Site
Nanjing, Jiangsu, China
Hutchison Medi Pharma Investigational Site
Nantong, Jiangsu, China
Hutchison Medi Pharma Investigational Site
Xuzhou, Jiangsu, China
Hutchison Medi Pharma Investigational Site
Changchun, Jilin, China
Hutchison Medi Pharma Investigational Site
Qingdao, Shandong, China
Hutchison Medi Pharma Investigational Site
Shanghai, Shanghai Municipality, China
Hutchison Medi Pharma Investigational Site
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.